Nano body inhibitors developed to target Ebola virus
Researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Centre have developed the first Nano-body-based inhibitors targeting the Ebola virus.
Researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first Nano-body -based inhibitors targeting the Ebola virus, including two new Nano-body inhibitors – Nanosota-EB1 and Nanosota-EB2.